Dr Chamaillard graduated his PhD in 2002 and has been appointed as a Research Director at Inserm in 2011 (H-index = 32 and 11,447 times cited without self-citations). At the Fondation Jean Dausset, he pioneered our understanding of the underlying mechanisms that are predisposing to inflammatory bowel diseases by contributing to the identification of NOD2 as the major Crohn's disease predisposing gene (Nature 2001) and then moved to the laboratory of Professor Gabriel Nunez at the University of Michigan to further elucidate the function of the NOD2 gene (EMBO J 2003 and Science 2005) and of its closest related molecule NOD1 (Nature Immunology 2003). Dr Chamaillard received several awards, including the Crohn's and Colitis Foundation of America Young Investigator Award in 2004 and the UEP Top Abstract Prize, and he has has been invited to several international meetings, including Keystone symposium, FALK symposium, European Immunology Group Meeting and International Congress of Mucosal Immunology.
Dr. Lionel Franz POULIN obtained his PhD in 2005 from the Free University of Brussels under the direction of Professor Michel Goldman. He has been appointed as a Research Associate at CNRS in 2014 (H-index = 10 and 1,546 times cited without self-citations). After his PhD, he moved to the laboratory of Professor Bernard Malissen at the Center of Immunology of Marseille-Luminy (CIML) where he contributed to the identification of mouse conventional type 1 dendritic cells (cDC1) within the skin dermis (Poulin et al., JEM 2007), and subsequently to their higher cross-presentation ability, a process aiming at presenting exogeneous antigens to CD8+ cytotoxic T-lymphocytes (Henri et al., JEM 2010). After this mouse discovery and thanks to a Marie-Curie fellowship, Dr Lionel Poulin moved to the laboratory of Professor Caetano Reis e Sousa at the Cancer Research UK London Research Institute (LRI), where he pioneered the DC characterization in human tissues and contributed to the identification of human cDC1 cells (Poulin et al., JEM 2010; Poulin et al., Blood 2012), these cells have been highlighted now as critical for immunotherapy success by stimulating anti-tumor immunity. Dr Poulin was awarded an ATIP-AVENIR grant from 2012 to 2016, which allow him to set up his laboratory and research activities at the Pasteur Institute of Lille, and he is member of administrative board of the French Dendritic Cell Society (CFCD) since 2013.